– Conference Call Today at 4:30 p.m. ET –SEATTLE (BUSINESS WIRE) Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and i.
/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the presentation of new investigational.
Management Team Mesoblast has a highly experienced management team made up of individuals who have held senior positions in international pharmaceutical and. | October 2, 2021
Aileron Therapeutics Reports Second Quarter 2021 Financial globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
email article
Donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell therapy led to complete responses in 18 of 20 patients with relapsed or refractory (r/r) T-cell acute lymphoblastic leukemia (ALL), a first-in-human clinical trial showed.
After a median follow-up of 6.3 months, 15 of the 18 responding patients remained in remission, and seven patients had undergone stem-cell transplantation (SCT). All patients developed cytokine release syndrome (CRS), which was grade 1/2 in most instances. Because the therapy involved unmanipulated T cells, a majority of patients developed graft-versus-host disease (GVHD), grade 1/2 severity in all cases. All of the patients developed severe cytopenias, which were manageable.
The results provided the basis for an ongoing phase II trial of the donor-derived anti-CD7 therapy, reported Jing Pan, MD, of the State Key Laboratory of Experimental Hematology and Beijing Boren Hospital in China, and colleagues in the